A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Public ClinicalTrials.gov record NCT03982186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA.
Study identification
- NCT ID
- NCT03982186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 471 participants
Conditions and interventions
Conditions
Interventions
- JNJ-73763989 Drug
- Placebo for JNJ-73763989 Drug
- JNJ-56136379 Drug
- Placebo for JNJ-56136379 Drug
- Nucleos(t)ide Analog (NA) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2019 (Actual)
- Primary completion
- Mar 29, 2021 (Actual)
- Completion
- Apr 26, 2022 (Actual)
- Last update posted
- Feb 4, 2025
2019 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Office of Franco Felizarta, MD | Bakersfield | California | 93301 | — |
| Ruane Clinical Research Group Inc | Los Angeles | California | 90036 | — |
| Southern California GI and Liver Center | San Clemente | California | 92673 | — |
| Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| I.D. Care, Inc. | Hillsborough | New Jersey | 08844 | — |
| NYU Hepatology Associates | New York | New York | 10016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03982186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03982186 live on ClinicalTrials.gov.